Catalyst Event
Innovent Biologics Inc (1801) · Other
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/24/2026, 12:00:00 AM
Announced that the Phase 3 STAR study of its eye disease drug Efdamrofusp Alfa (IBI302) met its primary endpoint, demonstrating non-inferiority to Eylea for treating neovascular age-related macular degeneration (nAMD). The drug also showed potential for less frequent dosing. [Estimate: Medium importance due to significant Phase 3 clinical milestone].
Korean Translation
안과 질환 치료제 이다무로푸스프 알파(IBI302)의 3상 임상(STAR 연구)이 주요 평가지표를 충족했다고 발표함. 신생혈관성 연령 관련 황반변성(nAMD) 치료에서 아일리아 대비 비열등성을 입증했으며, 투여 간격 연장 가능성을 보임. [예상: 주요 3상 임상 성공이라는 중대한 지표를 달성했으므로 'Medium'으로 분류함].
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM